Patents by Inventor Rémy Hanf

Rémy Hanf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treatment of cholestatic diseases
    Patent number: 12053445
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: August 6, 2024
    Assignee: GENFIT
    Inventor: Remy Hanf
  • NITAZOXANIDE IN THE TREATMENT OF SEPSIS
    Publication number: 20240238256
    Abstract: The present invention relates to a compound selected from nitazoxanide, tizoxanide and tizoxanide glucuronide, for use in a method for the treatment of sepsis in a subject in need thereof.
    Type: Application
    Filed: May 10, 2022
    Publication date: July 18, 2024
    Applicant: GENFIT
    Inventors: Vanessa LEGRY, Rémy HANF, Simon DEBAECKER
  • PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE
    Publication number: 20240216312
    Abstract: The invention relates to compounds for use in the treatment of liver failure.
    Type: Application
    Filed: May 10, 2022
    Publication date: July 4, 2024
    Inventors: Vanessa Legry, Remy Hanf, Simon Debaecker, Philippe Poulain, Benoit Noel
  • ELAFIBRANOR DERIVATIVES AGONISTS OF PPAR FOR USE IN THE TREATMENT OF SEPSIS
    Publication number: 20240216313
    Abstract: The invention relates to compounds for use in the treatment of sepsis.
    Type: Application
    Filed: May 10, 2022
    Publication date: July 4, 2024
    Inventors: Vanessa Legry, Remy Hanf, Simon Debaecker, Philippe Poulain, Benoit Noel, Robert Walczak, Peggy Parroche
  • METHODS OF TREATMENT OF CHOLESTATIC DISEASES
    Publication number: 20240156763
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Application
    Filed: November 9, 2023
    Publication date: May 16, 2024
    Inventor: Remy Hanf
  • METHODS OF TREATMENT OF CHOLESTATIC DISEASES
    Publication number: 20240091180
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5 -dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Application
    Filed: November 9, 2023
    Publication date: March 21, 2024
    Inventor: Remy Hanf
  • METHODS OF TREATMENT OF CHOLESTATIC DISEASES
    Publication number: 20240082185
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Application
    Filed: November 9, 2023
    Publication date: March 14, 2024
    Inventor: Remy Hanf
  • METHODS OF TREATMENT OF CHOLESTATIC DISEASES
    Publication number: 20240082186
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Application
    Filed: November 9, 2023
    Publication date: March 14, 2024
    Inventor: Remy Hanf
  • METHODS OF TREATMENT OF CHOLESTATIC DISEASES
    Publication number: 20240074999
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Application
    Filed: November 9, 2023
    Publication date: March 7, 2024
    Inventor: Remy Hanf
  • METHODS OF TREATMENT OF CHOLESTATIC DISEASES
    Publication number: 20240074998
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Application
    Filed: November 9, 2023
    Publication date: March 7, 2024
    Inventor: Remy Hanf
  • METHODS OF TREATMENT OF LIVER FAILURE
    Publication number: 20240000754
    Abstract: The invention relates to the treatment or prevention of liver failure.
    Type: Application
    Filed: November 16, 2021
    Publication date: January 4, 2024
    Inventors: Philippe DELATAILLE, Robert WALCZAK, Corinne FOUCART, Vanessa LEGRY, Nicolas STANKOVIC VALENTIN, Simon DEBAECKER, Rémy HANF
  • Methods of treatment of cholestatic diseases
    Patent number: 11857523
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: June 20, 2023
    Date of Patent: January 2, 2024
    Assignee: Genfit
    Inventor: Remy Hanf
  • Methods of treatment of cholestatic diseases
    Patent number: 11850223
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: June 20, 2023
    Date of Patent: December 26, 2023
    Assignee: Genfit
    Inventor: Remy Hanf
  • METHODS OF TREATMENT OF CHOLESTATIC DISEASES
    Publication number: 20230338312
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Application
    Filed: June 20, 2023
    Publication date: October 26, 2023
    Inventor: Remy Hanf
  • METHODS OF TREATMENT OF CHOLESTATIC DISEASES
    Publication number: 20230330048
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Application
    Filed: June 20, 2023
    Publication date: October 19, 2023
    Inventor: Remy Hanf
  • Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
    Patent number: 11519034
    Abstract: The present invention relates to a novel non-invasive method for the diagnosis of a non-alcoholic fatty liver disease, in particular non-alcoholic steatohepatitis, and/or liver fibrosis.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: December 6, 2022
    Assignee: Genfit
    Inventors: Remy Hanf, Genevieve Cordonnier, John Brozek
  • METHOD FOR TREATMENT OF AT RISK PATIENTS
    Publication number: 20220241232
    Abstract: The invention provides an anti-fibrotic or anti-nonalcoholic steatohepatitis (NASH) drug for use in a method for reducing the risk for a subject to develop liver fibrosis or NASH, wherein the drug is administered to a subject classified as at risk to develop liver fibrosis or NASH. The invention further provides an anti-fibrotic or anti-NASH substance for use in a method for the treatment of liver fibrosis or NASH, wherein the drug is administered to a subject having type 2 diabetes.
    Type: Application
    Filed: June 8, 2020
    Publication date: August 4, 2022
    Inventors: JOHN BROZEK, NOÉMIE DAM, YACINE HAJJI, RÉMY HANF
  • Methods of treatment of cholestatic diseases
    Patent number: 11331292
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: May 17, 2022
    Assignee: Genfit
    Inventor: Remy Hanf
  • METHODS OF TREATMENT OF CHOLESTATIC DISEASES
    Publication number: 20220133666
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Application
    Filed: November 23, 2021
    Publication date: May 5, 2022
    Inventor: Remy Hanf
  • Methods of treatment of cholestatic diseases
    Patent number: 11185519
    Abstract: The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: November 30, 2021
    Assignee: Genfit
    Inventor: Rémy Hanf